Gregory Bremer

Gregory Bremer is an experienced professional in upstream process development, currently serving as Director of Upstream Process Development at Ensoma since April 2021, where the focus is on adenoviral vector gene therapies. Prior to this role, Gregory held the position of Associate Director of Upstream Process Development at Leap Therapeutics, leading upstream development for antibody therapies. With a solid background at Sartorius Stedim Biotech as Manager of Upstream Engineering and previous roles at Gallus BioPharmaceuticals as Scientist III and various internships, Gregory has developed expertise in bioreactor technologies, media products, and cell culture process optimization. Gregory holds a Master of Science in Management and a Bachelor’s degree in Biomedical Engineering, both from Stevens Institute of Technology.